NASDAQ · OABIW
Healthcare · Biotechnology
$0.37
Down-$0.17 (-45.58%)
Updated Sep 21, 2026, 4:51 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 11 trading sessions · Daily adjusted prices
OABIW closed at $0.37 after 11 trading sessions, up 58.06% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $0.3675 | $0.3675 | $0.3675 | $0.3675 | 1.79K |
| Sep 8, 2026 | $0.34 | $0.34 | $0.34 | $0.34 | 159 |
| Sep 4, 2026 | $0.39 | $0.39 | $0.39 | $0.39 | 330 |
| Sep 3, 2026 | $0.34 | $0.3862 | $0.34 | $0.3862 | 2.36K |
| Sep 2, 2026 | $0.26 | $0.422 | $0.26 | $0.3509 | 120.96K |
| Aug 31, 2026 | $0.28 | $0.28 | $0.25 | $0.26 | 3.17K |
| Aug 28, 2026 | $0.25 | $0.25 | $0.25 | $0.25 | 1.07K |
| Aug 27, 2026 | $0.25 | $0.325 | $0.25 | $0.25 | 7.93K |
| Aug 26, 2026 | $0.23 | $0.3255 | $0.1975 | $0.30 | 15.49K |
| Aug 25, 2026 | $0.23 | $0.2424 | $0.18 | $0.23 | 15.16K |
| Aug 24, 2026 | $0.2339 | $0.2339 | $0.18 | $0.2325 | 12.74K |
The latest Smart Investors Daily articles mentioning OABIW.
OABIW research
Company profile and research snapshot.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Sep 14, 2026
EMERYVILLE, Calif., September 14, 2026--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reiterates details of its upcoming Investor & Analyst Day, to be held on October 6, 2026, in Emeryville, CA.
Yahoo · Aug 28, 2026
On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveraging OmniAb’s specialized antibody discovery platform, the deal grants Lilly exclusive global rights to commercialize resulting candidates in exchange for an upfront payment, up to $370 million in […]
Yahoo · Aug 28, 2026
VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate ("AOC") developed through their research alliance. The AOC candidate demonstrated greater potency than the equiva...
SeekingAlpha · Aug 7, 2026
2026-08-07. The following slide deck was published by OmniAb, Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OABIW.
No results
No recent SID articles mention OABIW.
